These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 22832234)

  • 1. Overcoming the challenges to developing new antibiotics.
    Shlaes DM; Spellberg B
    Curr Opin Pharmacol; 2012 Oct; 12(5):522-6. PubMed ID: 22832234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotics in the intensive care unit: focus on agents for resistant pathogens.
    Volles DF; Branan TN
    Emerg Med Clin North Am; 2008 Aug; 26(3):813-34, x. PubMed ID: 18655946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active controlled studies in antibiotic drug development.
    Dane A
    Pharm Stat; 2011; 10(5):454-60. PubMed ID: 21956949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens.
    Alemayehu D; Quinn J; Cook J; Kunkel M; Knirsch CA
    Clin Infect Dis; 2012 Aug; 55(4):562-7. PubMed ID: 22610933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic discovery in the twenty-first century: current trends and future perspectives.
    Donadio S; Maffioli S; Monciardini P; Sosio M; Jabes D
    J Antibiot (Tokyo); 2010 Aug; 63(8):423-30. PubMed ID: 20551985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Available laboratory tests to guide antimicrobial therapy.
    Araj GF
    J Med Liban; 2000; 48(4):199-202. PubMed ID: 11214189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bacteriologic and clinical analysis of nosocomial infections in patients from the intensive care unit].
    Nikodemski T
    Ann Acad Med Stetin; 1999; 45():211-26. PubMed ID: 10909491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and challenges of developing new agents for tough Gram-negatives.
    Meyer AL
    Curr Opin Pharmacol; 2005 Oct; 5(5):490-4. PubMed ID: 16084769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of antibacterial discovery revisited.
    Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
    Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbial resistance to drugs--a universal problem in urgent need of a comprehensive approach.
    Kumar A
    Natl Med J India; 1997; 10(5):221-4. PubMed ID: 9401381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for new antibiotics.
    Livermore DM
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():1-9. PubMed ID: 15522034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma.
    Löscher W; Schmidt D
    Epilepsia; 2011 Apr; 52(4):657-78. PubMed ID: 21426333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibiotic therapy in infections caused by resistant strains of bacteria].
    Marshak AM; Solov'eva VE
    Voen Med Zh; 1969 Feb; 2():38-44. PubMed ID: 5772335
    [No Abstract]   [Full Text] [Related]  

  • 19. Choice of delta noninferiority margin and dependency of the noninferiority trials.
    Tsong Y; Zhang J; Levenson M
    J Biopharm Stat; 2007; 17(2):279-88. PubMed ID: 17365224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
    Corey GR; Stryjewski ME
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.